Compare Ascendis Pharma A/S (ASND) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Zeta Global Holdings Corp — how do they compare? Ascendis Pharma A/S trades at $265.03 (market cap $17.74B), while Zeta Global Holdings Corp trades at $21.73 (market cap $5.36B). The key difference: Ascendis Pharma A/S is far larger — about 3.3× Zeta Global Holdings Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Zeta Global Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ASND | ZETA | |
|---|---|---|
Market Cap | $17.74B | $5.36B |
Sector | Health | Technology |
52-Week High | $277.18 | $25.24 |
52-Week Low | $163.32 | $14.00 |
Enterprise Value | $18.11B | $5.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ZETA trades at $21.49, down 1.94% on the day, with a bullish technical signal from moving averages and strong analyst support. The company demonstrates robust revenue growth, reaching $1.30B in 2025, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its strategic AI partnership with Palantir and expansion of its Athena AI platform, driving positive investor sentiment despite current negative profitability metrics.
The outlook for ZETA is positive, with a consensus price target of $27.50 implying 28% upside. Key opportunities include AI-driven growth and market share gains, but risks involve persistent negative net margins and cash flow challenges. Investors should weigh the strong growth trajectory against profitability concerns before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
